Description
Naquotinib is a potent, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor that displays antineoplastic activity. Naquotinib preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.
Naquotinib is a potent, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor that displays antineoplastic activity. Naquotinib preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.
Alternate Name/Synonyms: (R)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide; ASP8273
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 448232-80-1
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₃₀H₄₂N₈O₃
Molecular Weight: 562.72
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor
MDL Number: N/A
PubChem CID: 71667668
SMILES: CCC1=NC(=C(N=C1OC2CCN(C2)C(=O)C=C)NC3=CC=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)C(=O)N
InChi: CCC1=NC(=C(N=C1O[C@@H]2CCN(C2)C(=O)C=C)NC3=CC=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)C(=O)N
InChi Key: QKDCLUARMDUUKN-XMMPIXPASA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |